Pharmacokinetics and Tolerability of Etamicastat Following Single and Repeated Administration in Elderly Versus Young Healthy Male Subjects: An Open-Label, Single-Center, Parallel-Group Study

Clinical Therapeutics

Volumn 33, Issue 6, 2011, Pages 776-791

  Nunes, Teresa ^a   Rocha, José Francisco ^a   Vaz da Silva, Manuel ^a   Falcão, Amilcar ^b   Almeida, Luis ^c   Soares da Silva, Patricio ^a,d  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d University of Porto   (Portugal)

Author keywords

Age effect; Dopamine hydroxylase; Dopamine hydroxylase inhibition; Etamicastat; Heart failure; Hypertension; Pharmacokinetics

Indexed keywords

ACYLTRANSFERASE; ETAMICASTAT;

ADULT; AGED; ARTICLE; ASTHENIA; BACKACHE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG TOLERABILITY; EXPOSURE; GENOTYPE; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; INSOMNIA; ISCHIALGIA; MALE; MAXIMUM PLASMA CONCENTRATION; PAIN; SINGLE DRUG DOSE; SORE THROAT; STATISTICAL SIGNIFICANCE; STEADY STATE; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AREA UNDER CURVE; ARYLAMINE N-ACETYLTRANSFERASE; BENZOPYRANS; DOPAMINE BETA-HYDROXYLASE; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; GENOTYPE; HUMANS; IMIDAZOLES; ISOENZYMES; MALE; TIME FACTORS; YOUNG ADULT;

EID: 79959484783     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.05.048     Document Type: Article

References (36)

1. Esler M., Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol 2000, 35(Suppl 4):S1-S7.
2. Grassi G., Bolla G., Quarti-Trevano F., et al. Sympathetic activation in congestive heart failure: reproducibility of neuroadrenergic markers. Eur J Heart Fail 2008, 10:1186-1191.
3. Grassi G., Seravalle G., Quarti-Trevano F. The 'neuroadrenergic hypothesis' in hypertension: current evidence. Exp Physiol 2010, 95:581-586.
4. Lee C.S., Tkacs N.C. Current concepts of neurohormonal activation in heart failure: mediators and mechanisms. AACN Adv Crit Care 2008, 19:364-385.
5. Mancia G., Grassi G., Giannattasio C., Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999, 34:724-728.
6. Parmley W.W. Neuroendocrine changes in heart failure and their clinical relevance. Clin Cardiol 1995, 18:440-445.
7. Pfeffer M.A., Stevenson L.W. Beta-adrenergic blockers and survival in heart failure. N Engl J Med 1996, 334:1396-1397.
8. Stanley W.C., Li B., Bonhaus D.W., et al. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol 1997, 121:1803-1809.
9. Hegde S.S., Friday K.F. Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure. Curr Pharm Des 1998, 4:469-479.
10. Soares-da-Silva P. Evidence for a non-precursor dopamine pool in noradrenergic neurones of the dog mesenteric artery. Naunyn Schmiedebergs Arch Pharmacol 1986, 333:219-223.
11. Soares-da-Silva P. A comparison between the pattern of dopamine and noradrenaline release from sympathetic neurones of the dog mesenteric artery. Br J Pharmacol 1987, 90:91-98.
12. Gomes P., Soares-da-Silva P. Dopamine. Cardiovascular Hormone Systems: From Molecular Mechanisms to Novel Therapeutics 2008, 251-293. Wiley-VCH, Weinheim. M. Baden (Ed.).
13. Jose P.A., Eisner G.M., Felder R.A. Role of dopamine receptors in the kidney in the regulation of blood pressure. Curr Opin Nephrol Hypertens 2002, 11:87-92.
14. Goldstein M., Anagnoste B., Lauber E., McKeregham M.R. Inhibition of dopamine-beta-hydroxylase by disulfiram. Life Sci 1964, 3:763-767.
15. Lippmann W., Lloyd K. Dopamine-β-hydroxylase inhibition by dimethyldithiocarbamate and related compounds. Biochem Pharmacol 1969, 18:2507-2516.
16. Hidaka H. Fusaric (5-butylpicolinic) acid, an inhibitor of dopamine beta-hydroxylase, affects serotonin and noradrenaline. Nature 1971, 231:54-55.
17. Johnson G.A., Boukma S.J., Kim E.G. In vivo inhibition of dopamine beta-hydroxylase by 1-phenyl-3-(2-thiazolyl)-2-thiourea (U-14,624). J Pharmacol Exp Ther 1970, 171:80-87.
18. Hegde S.S., Friday K.F. Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure. Curr Pharma Design 1998, 4:469-479.
19. Bonifácio M.J., Igreja B., Wright L., Soares-da-Silva P. Kinetic studies on the inhibition of dopamine-β-hydroxylase by BIA 5-453 [abstract]. pA2 online 2009, 7:050P.
20. Beliaev A., Learmonth D.A., Soares-da-Silva P. Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine beta-hydroxylase. J Med Chem 2006, 49:1191-1197.
21. Igreja B., Wright L., Soares-da-Silva P. Sustained antihypertensive effects of a selective peripheral dopamine-β-hydroxylase iInhibitor [abstract]. Hypertension 2007, 50:e133.
22. Igreja B., Wright L., Soares-da-Silva P. Long-term lowering of blood pressure levels in the SHR by selective peripheral inhibition of dopamine-b-hydroxylase with BIA 5-453 [abstract]. pA2 online 2008, 6:087P.
23. Wright L., Soares-da-Silva P. Long-term benefits of the selective peripheral dopamine-β-hydroxylase inhibitor BIA 5-453 in heart failure [abstract]. pA2 online 2008, 6:088P.
24. Igreja B., Loureiro A.I., Fernandes-Lopes C., et al. Interspecies differences in pharmacodynamic and disposition of BIA 5-453, a novel dopamine-beta-hydroxylase inhibitor [abstract]. Drug Metabol Rev 2009, 40:39-40.
25. Beliaev A., Ferreira H., Learmonth D.L., Soares-da-Silva P. Dopamine beta-monooxygenase: mechanism, substrates and inhibitors. Curr Enzyme Inh 2009, 5:27-43.
26. Rocha J.F., Vaz-da-Silva M., Nunes T., et al. Single-dose tolerability, pharmacokinetics and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine beta-hydroxylase inhibitor, in healthy subjects. J Clin Pharmacol 2011, 10.1177/0091270010390805.
27. Nunes T., Rocha J.F., Vaz-da-Silva M., et al. Safety, tolerability and pharmacokinetics of etamicastat, a novel dopamine-beta-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. Drugs R&D 2010, 10:225-242.
28. Fronhoffs S., Bruning T., Ortiz-Pallardo E., et al. Real-time PCR analysis of the N-acetyltransferase NAT1 allele *3, *4, *10, *11, *14 and *17 polymorphism in squamous cell cancer of head and neck. Carcinogenesis 2001, 22:1405-1412.
29. Li D., Jiao L., Li Y., et al. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 2006, 27:103-111.
30. Brocvielle H., Muret P., Goydadin A.C., et al. N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects. Skin Pharmacol Appl Skin Physiol 2003, 16:386-392.
31. Rychlik-Sych M., Skretkowicz J., Gawronska-Szklarz B., et al. Acetylation genotype and phenotype in patients with systemic lupus erythematosus. Pharmacol Rep 2006, 58:22-29.
32. Chow S.-C., Wang H. On sample size calculation in bioequivalence trials. J Pharmacokin Pharmacodyn 2001, 28:155-169.
33. Gabrielsson J., Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts & Applications 2000, Swedish Pharmaceutical Press, Stockolm. 3rd ed.
34. Guidance for industry. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs FDA/CDER, Accessed June 3, 2011. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129357.pdf.
35. Guidance for industry. E7: Guidance for Industry -Studies in Support of Special Populations: Geriatrics FDA/CDER, Accessed June 3, 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073131.pdf.
36. E7 Studies in Support of Special Populations: Geriatrics. Questions & Answers International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, Accessed June 3, 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM189544.pdf.